Easnings call Transcript date 16th February, 2026

Sanjivani Paranteral reported strong Q3 FY26 results with standalone revenue of INR 20.9 crores (+20.2% YoY), driven by better export shipments and improved product mix. EBITDA grew 36% YoY to INR 3.9 crores with margin expanding from 16.2% to 18.4%. On a consolidated basis, revenue rose 27.1% YoY to INR 22.1 crores, aided by the first-ever revenue contribution of INR 1.2 crores from its Pune IV infusion subsidiary (SPL Infusion). Management guided FY26 base business revenue at INR 72-75 crores and FY27 at INR 90 crores, with SPL Infusion expected to add INR 60-65 crores in FY27 and reach a peak of INR 120-130 crores. The company confirmed all promoter warrants have been fully converted with money received, and noted all plants are compliant with the revised Schedule M norms.